Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Switch Interest Cooled By Study Costs To Update Safety Data

Executive Summary

Firms often are hesitant to prepare Rx-to-OTC switch applications because safety and efficacy data for their products are over a decade old, notes health care consultant Laura Mahecha.

Advertisement

Related Content

FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap
Petition Seeks OTC PPI Warning On Cancer Risk From Persistent Heartburn
Pharma Firm ISO OTC Switch Partner; NDA Experience, Resources Needed
Differin Gel Enters Changed Marketplace Since Last OTC Acne Drug Approval
Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook
Light Still On For Switches After Pfizer Pulls Plug On OTC Lipitor
Room For Innovative Switches Could Lurk In Existing FDA Framework
Naloxone Talk Sheds Light On Switch Research Future

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120992

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel